Pericor Science Finds Advance in Thrombin Inhibitor Research
Results show compound prevents thrombosis and restenosis following angioplasty.!--h2>
Pericor Science reported that an ex vivo study (pig coronary artery) demonstrated that the company’s new compound covalently attaches to the inner lumen of the coronary artery with uniform mural coverage and penetration and retains its therapeutic activity by binding to thrombin. Thrombin is an enzyme that plays a central role in the formation of blood clots and cell growth in the injured coronary artery.
Pericor researchers believe this development could result in a drug for interventional cardiology that will prevent thrombosis and restenosis and not retard healing of the blood vessel. Restenosis is the re-narrowing of a coronary artery after it has been treated with angioplasty or stenting.